Linzey Joseph R, Marini Bernard, McFadden Kathryn, Lorenzana Adonis, Mody Rajen, Robertson Patricia L, Koschmann Carl
1Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI 48109 USA.
2Department of Pharmacy Services, University of Michigan Medical School, Ann Arbor, MI 48109 USA.
NPJ Precis Oncol. 2017 Sep 7;1(1):29. doi: 10.1038/s41698-017-0036-8. eCollection 2017.
Approximately 1-5% of pediatric intracranial tumors originate in the thalamus. While great strides have been made to identify consistent molecular markers in adult oligodendrogliomas, such as the 1p/19q co-deletion, it is widely recognized that pediatric oligodendrogliomas have a vastly different molecular make-up. While pediatric thalamic or "central oligodendrogliomas" are histologically similar to peripheral pediatric oligodendrogliomas, they are behaviorally distinct and likely represent a cohesive, but entirely different entity. We describe a case of a 10-year-old girl who was diagnosed with an anaplastic glioma with features consistent with the aggressive entity often diagnosed as central or thalamic oligodendroglioma. We performed whole-exome (paired tumor and germline DNA) and transcriptome (tumor RNA) sequencing, which demonstrated an fusion. We describe this fusion and our rationale for pursuing personalized, targeted therapy for the patient's tumor that may potentially play a role in the treatment of similar cases.
约1%-5%的儿童颅内肿瘤起源于丘脑。虽然在识别成人少突胶质细胞瘤的一致分子标志物方面已取得巨大进展,如1p/19q共缺失,但人们普遍认识到儿童少突胶质细胞瘤具有截然不同的分子构成。虽然儿童丘脑或“中枢少突胶质细胞瘤”在组织学上与外周儿童少突胶质细胞瘤相似,但它们在行为上有所不同,可能代表一个有凝聚力但完全不同的实体。我们描述了一例10岁女孩的病例,她被诊断为间变性胶质瘤,其特征与通常被诊断为中枢或丘脑少突胶质细胞瘤的侵袭性实体一致。我们进行了全外显子组(配对肿瘤和种系DNA)和转录组(肿瘤RNA)测序,结果显示了一种融合。我们描述了这种融合以及我们为该患者肿瘤寻求个性化靶向治疗的基本原理,这可能对类似病例的治疗起到作用。